Table 3 |
|||
|
Selected auxological and hormonal data of the patients according to thyroid function during rhGH administration |
|||
|
euthyroid |
hypothyroid |
p |
|
|
|
|||
|
n |
50 |
17 |
|
|
|
|||
|
Before rhGH administration |
|||
|
|
|||
|
age [years] |
12.4 ± 2.3 |
12.3 ± 2.1 |
0.94 |
|
|
|||
|
height SDS |
-2.60 ± 0.50 |
-2.77 ± 0.63 |
0.38 |
|
|
|||
|
HV [cm/year] |
3.5 ± 1.0 |
3.8 ± 0.9 |
0.14 |
|
|
|||
|
TSH [mU/l] |
2.22 ± 0.95 |
2.65 ± 0.92 |
0.05 |
|
|
|||
|
FT4 [ng/dl] |
1.33 ± 0.15 |
1.21 ± 0.11 |
0.01 |
|
|
|||
|
IGF-I SDS |
-2,01 ± 0.97 |
-1.99 ± 1.00 |
0.45 |
|
|
|||
|
IGF-I/IGFBP-3 |
0.19 ± 0.07 |
0.18 ± 0.05 |
0.71 |
|
|
|||
|
After 3-6 months of rhGH therapy |
|||
|
|
|||
|
TSH [mU/l] |
2.25 ± 0.92 |
3.71 ± 1.75 |
< 0.001 |
|
|
|||
|
FT4 [ng/dl] |
1.16 ± 0.10 |
1.01 ± 0.14 |
< 0.001 |
|
|
|||
|
IGF-I SDS |
0.37 ± 0.81 |
0.54 ± 0.81 |
0.59 |
|
|
|||
|
IGF-I/IGFBP-3 |
0.38 ± 0.11 |
0.42 ± 0.12 |
0.36 |
|
|
|||
|
After 1 year of rhGH therapy |
|||
|
|
|||
|
TSH [mU/l] |
2.07 ± 0.98 |
2.16 ± 0.79 |
0.54 |
|
|
|||
|
FT4 [ng/dl] |
1.31 ± 0.15 |
1.23 ± 0.14 |
0.11 |
|
|
|||
|
IGF-I SDS |
0.61 ± 0.67 |
0.83 ± 0.83 |
0.35 |
|
|
|||
|
IGF-I/IGFBP-3 |
0.41 ± 0.09 |
0.45 ± 0.12 |
0.84 |
|
|
|||
|
HV [cm/year] |
10.0 ± 2.1 |
9.3 ± 2.0 |
0.23 |
|
|
|||
|
ΔHV [cm/year] |
6.5 ± 2.3 |
5.4 ± 2.1 |
0.01 |
|
|
|||
|
ΔHV [%] |
213 ± 118 |
154 ± 85 |
0.05 |
|
|
|||
|
Smyczynska et al. Thyroid Research 2010 3:2 doi:10.1186/1756-6614-3-2 |
|||
